Aptevo Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aptevo Therapeutics (APVO).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$106560Upside to Avg. PT+6380738.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2024	Roth MKM	Jonathan Aschoff	PT Cut	Buy	$199800→$106560

Analyst Ratings News

PRO
Watching Aptevo Therapeutics; Zacks Small-Cap Research Gives Stock $30 Price Valuation

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $8

Roth MKM analyst Jonathan Aschoff maintains Aptevo Therapeutics (NASDAQ:APVO) with a Buy and lowers the price target from $15 to $8.

Benzinga Newsdesk

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is simple — when a stock's current market price does not adequately reflect its higher earnings, it suggests potential for growth.

Zacks

PRO
Piper Sandler Maintains Overweight on Aptevo Therapeutics, Lowers Price Target to $20

Piper Sandler analyst Edward Tenthoff maintains Aptevo Therapeutics (NASDAQ:APVO) with a Overweight and lowers the price target from $69 to $20.

Benzinga Newsdesk

PRO
Roth Capital Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $50

Roth Capital analyst Jonathan Aschoff maintains Aptevo Therapeutics (NASDAQ:APVO) with a Buy and lowers the price target from $64 to $50.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Aptevo Therapeutics, Raises Price Target to $69

Piper Sandler analyst Edward Tenthoff maintains Aptevo Therapeutics (NASDAQ:APVO) with a Overweight and raises the price target from $32 to $69.

Benzinga Newsdesk

Aptevo Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aptevo Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Watching Aptevo Therapeutics; Zacks Small-Cap Research Gives Stock $30 Price Valuation

PRO
Roth MKM Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $8

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

PRO
Piper Sandler Maintains Overweight on Aptevo Therapeutics, Lowers Price Target to $20

PRO
Roth Capital Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $50

PRO
Piper Sandler Maintains Overweight on Aptevo Therapeutics, Raises Price Target to $69

People Also Watch

People Also Watch

Aptevo Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aptevo Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWatching Aptevo Therapeutics; Zacks Small-Cap Research Gives Stock $30 Price Valuation

PRORoth MKM Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $8

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

PROPiper Sandler Maintains Overweight on Aptevo Therapeutics, Lowers Price Target to $20

PRORoth Capital Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $50

PROPiper Sandler Maintains Overweight on Aptevo Therapeutics, Raises Price Target to $69

People Also Watch

People Also Watch

PRO
Watching Aptevo Therapeutics; Zacks Small-Cap Research Gives Stock $30 Price Valuation

PRO
Roth MKM Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $8

PRO
Piper Sandler Maintains Overweight on Aptevo Therapeutics, Lowers Price Target to $20

PRO
Roth Capital Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $50

PRO
Piper Sandler Maintains Overweight on Aptevo Therapeutics, Raises Price Target to $69